Comparing the current results to its competitors, Puma Biotechnology Inc reported Revenue increase in the 2 quarter 2026 by 7.75 % year on year. The sales growth was above Puma Biotechnology Inc 's competitors' average revenue growth of 6.93 %, achieved in the same quarter.
Puma Biotechnology Inc Net Income in the 2 quarter 2026 grew year on year by 39.86%, while most of its competitors have experienced a contraction in net income by -81.55 %.
Puma Biotechnology Inc 's Comment on Competition and Industry Peers
The company operates in a competitive cancer treatment market alongside major pharmaceutical, biotechnology, and specialty cancer firms. Competitors include Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz, and Seagen. Merck, AbbVie, Amgen, Daiichi Sankyo, and Jazz are developing drugs for small cell lung cancer, while the others focus on early-stage and metastatic HER2-positive breast cancer or related cancer types. The company notes that many competitors possess greater financial resources and expertise in drug development and commercialization. Industry mergers and acquisitions may further consolidate resources among fewer competitors. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies.
With revenue growth of 7.75 % within Overall company, Puma Biotechnology Inc achieved improvement in market share, within Overall company to approximately 0.07 %. << More on PBYI Market Share.
*Market share is calculated based on total revenue.
February 27, 2025
for CSIMarket.com : Comparative Financial Performance and Market Positioning of Puma Biotechnology Inc. In an era where biopharmaceutical companies are pivotal in developing innovative therapies, Puma Biotechnology Inc. (NASDAQ: PBYI) has demonstrated ...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pacira Biosciences Inc is a pharmaceutical company that focuses on the development and commercialization of non-opioid pain management products and treatments.
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies delivered through its proprietary device called Optinose Exhalation Delivery System. They generate revenue by licensing and selling their treatment products for conditions like nasal polyps and migraines.
Sources:
Puma Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Puma Biotechnology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
